846036-96-2

Usage

Uses

Used in Pharmaceutical Industry:
(4-aMino-6-chloropyridin-3-yl)Methanol is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure and properties make it a valuable component in the development of new drugs, particularly in medicinal chemistry.
Used in Agrochemical Industry:
In the agrochemical industry, (4-aMino-6-chloropyridin-3-yl)Methanol serves as an essential intermediate in the production of pesticides. Its presence in these compounds contributes to their effectiveness in controlling pests and protecting crops.
Used as a Chemical Intermediate:
(4-aMino-6-chloropyridin-3-yl)Methanol is used as a chemical intermediate in the synthesis of a wide range of chemicals. Its versatility allows it to be incorporated into various chemical processes, leading to the creation of new compounds with diverse applications.
It is crucial to handle (4-aMino-6-chloropyridin-3-yl)Methanol with care due to its potential hazards if not properly managed. Proper safety measures should be taken to ensure the safe use of (4-aMino-6-chloropyridin-3-yl)Methanol in various industries.

Upstream product

• 6975-44-6 4,6-dihydroxynicotinic acid ethyl ester 
• 105-50-0 diethyl 1,3-acetonedicarboxylate 
• 1588423-42-0 ethyl 6-chloro-4-((2,4-dimethoxybenzyl)amino)nicotinate 
• 1830-54-2 3-oxopentanedioic acid dimethyl ester 
• 1256785-40-6 methyl 4-amino-6-chloro-pyridine-3-carboxylate 
• 1374215-05-0 methyl 4-(benzylamino)-6-chloronicotinate 
• 65973-52-6 methyl 4,6-dichloropyridine-3-carboxylate 
• 79398-27-9 methyl 4,6-dihydroxypyridine-3-carboxylate 
• 380626-81-3 ethyl 4-amino-6-chloropyridine-3-carboxylate 
• 1391740-89-8 ethyl 6-chloro-4-[(4-methoxyphenyl)methylamino]pyridine-3-carboxylate 
• 40296-46-6 ethyl 4,6-dichloronicotinate 

Downstream Products

• 1001756-21-3 4-amino-6-chloropyridine-3-carboxaldehyde 
• 1386447-86-4 3-({7-[(2,2-dimethyl-[1,3]dioxolan-4-ylmethyl)-amino]-2-oxo-1,2-dihydro-[1,6]naphthyridine-3-carbonyl}-amino)-benzoic acid methyl ester 
• 1588422-41-6 C₃₁H₃₁N₅O₂ 
• 1588422-66-5 3-(2,6-difluorophenyl)-7-((5-fluoropyridin-2-yl)amino)-1-phenyl-1,6-naphthyridin-2(1H)-one 
• 1588423-43-1 C₁₄H₉ClN₂O 
• 1588423-57-7 C₁₄H₇ClF₂N₂O 
• 1588423-58-8 C₂₀H₁₁ClF₂N₂O 
• 1588423-92-0 C₂₀H₁₃ClN₂O 
• 1588423-93-1 C₁₇H₁₅ClN₂O 
• 1588421-99-1 7-[5-(2-diethylaminoethoxy)pyridin-2-ylamino]-3-phenyl-1H-[1,6]naphthyridin-2-one 
• 1588422-00-7 7-[5-(2-diethylaminoethoxy)pyridin-2-ylamino]-1-methyl-3-phenyl-1H-[1,6]naphthyridin-2-one 
• 1588422-03-0 7-[5-(2-diethylaminoethoxy)pyridin-2-ylamino]-3-isopropyl-1-phenyl-1H-[1,6]naphthyridin-2-one 
• 1455037-49-6 1-(3,3-dimethylbutyl)-3-(2-fluoro-5-(7-((4-methoxybenzyl)(methyl)amino)-2-methyl-1,6-naphthyridin-3-yl)-4-methylphenyl)urea 
• 1455036-70-0 prop-1-en-2-yl (2-fluoro-5-(7-((4-methoxybenzyl)(methyl)amino)-2-methyl[1,6]naphthyridin-3-yl)-4-methylphenyl)carbamate 

Relevant academic research and scientific papers

UREA COMPOUNDS AND COMPOSITIONS AS SMARCA2/BRM ATPASE INHIBITORS

A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a BRM-mediated and/or BRG1-mediated disease or disorder: Formula (I) wherein R1 through R6 are as defined herein.

Discovery of Orally Active Inhibitors of Brahma Homolog (BRM)/SMARCA2 ATPase Activity for the Treatment of Brahma Related Gene 1 (BRG1)/SMARCA4-Mutant Cancers

SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin subfamily A member 2 (SMARCA2), also known as Brahma homologue (BRM), is a Snf2-family DNA-dependent ATPase. BRM and its close homologue Brahma-related gene 1 (BRG1), also known as SMARCA4, are mutually exclusive ATPases of the large ATP-dependent SWI/SNF chromatin-remodeling complexes involved in transcriptional regulation of gene expression. No small molecules have been reported that modulate SWI/SNF chromatin-remodeling activity via inhibition of its ATPase activity, an important goal given the well-established dependence of BRG1-deficient cancers on BRM. Here, we describe allosteric dual BRM and BRG1 inhibitors that downregulate BRM-dependent gene expression and show antiproliferative activity in a BRG1-mutant-lung-tumor xenograft model upon oral administration. These compounds represent useful tools for understanding the functions of BRM in BRG1-loss-of-function settings and should enable probing the role of SWI/SNF functions more broadly in different cancer contexts and those of other diseases.

CHEMICAL COMPOUNDS AS H-PGDS INHIBITORS

A compound of formula (I) wherein R1, R2, R3, R4, X, Y, and A are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne muscular dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS

Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for

Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3- d ]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells

The RAS-RAF-MEK-MAPK cascade is an essential signaling pathway, with activation typically mediated through cell surface receptors. The kinase inhibitors vemurafenib and dabrafenib, which target oncogenic BRAF V600E, have shown significant clinical efficac

HETEROCYCLIC COMPOUND

Provided is a compound having a superior FLAP inhibitory action and useful as a prophylactic or therapeutic agent for arteriosclerosis and the like, and a salt thereof. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the present DESCRIPTION, or a salt thereof.

MULTIPLE KINASE PATHWAY INHIBITORS

Kinase with inhibitory activity against kinases disposed in multiple signaling pathways and their therapeutic uses.

RAF INHIBITOR COMPOUNDS

This invention provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula (I); and use of a compound of Formula (I) for treating specified cancers.

1,6- AND 1,8-NAPHTHYRIDINES

Compounds of formula and pharmaceutically acceptable salts thereof are described, as well as the pharmaceutical compositions containing said compounds and their pharmaceutically acceptable salts, and the use of said compounds and pharmaceutical compositions for the treatment, control or amelioration of proliferative diseases, including cancer, Down syndrome or early onset Alzheimer's disease.

[1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia

This invention relates to compounds of the formula 1 wherein G, D, A, Z, Q, X, Y, R1, and R4 through R7 are defined as in the specification, processes for preparing the same and intermediates used in making the same, and pharmaceutical compositions containing such compounds and their use in the treatment of central nervous system disorders and other disorders.